Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 645

The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

Open access
Herrmann, Joerg, Lenihan, Daniel, Armenian, Saro, Barac, Ana, Blaes, Anne, Cardinale, Daniela, Carver, Joseph, Dent, Susan, Ky, Bonnie, Lyon, Alexander R, López-Fernández, Teresa, Fradley, Michael G, Ganatra, Sarju, Curigliano, Giuseppe, Mitchell, Joshua D, Minotti, Giorgio, Lang, Ninian N, Liu, Jennifer E, Neilan, Tomas G, Nohria, Anju, O'Quinn, Rupal, Pusic, Iskra, Porter, Charles, Reynolds, Kerry L, Ruddy, Kathryn J, Thavendiranathan, Paaladinesh, Valent, Peter·2022·European Heart Journal

Abstract

The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab674

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 122 references

Cited by

See all 645

Metadata

Authors
Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., Nohria, A., O'Quinn, R., Pusic, I., Porter, C., Reynolds, K. L., Ruddy, K. J., Thavendiranathan, P., & Valent, P.
Venue
European Heart Journal
Published
2021-12-14
Volume
43
Issue
4
Pages
280-299
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3204395813
Cited by
645
References
122
FWCI
52.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. https://app.cochat.ai/papers/10.1093/eurheartj/ehab674
The paper
Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., . . . Valent, P. (2022). Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab674

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.